Vimentin Antibody (YA3714)

Art. -Nr.: HY-P84017: Data Sheet User Guide for Antibodies
FAQs
Technical Support

Vimentin Antibody (YA3714) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Vimentin.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Größe	Verfügbarkeit	Menge
20 μL	Angebot einholen 2 - 3 Weeks 1 - 2 Weeks 3 - 4 Weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
50 μL	Angebot einholen 2 - 3 Weeks 1 - 2 Weeks 3 - 4 Weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
100 μL	Angebot einholen 2 - 3 Weeks 1 - 2 Weeks 3 - 4 Weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
250 μL	Angebot einholen

Synthetic products have potential research and development risk.

or Massenanfrage

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Beschreibung

Beschreibung

Vimentin Antibody (YA3714) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Vimentin.

Host

Mouse

Clonality

Monoclonal Antibody

Molekulargewicht

Predicted band size: 54 kDa;

Observed band size: 54 kDa

Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.

Species Reactivity

Human, Mouse, Rat

SwissProt ID

P08670

Gene ID

7431 [NCBI]

Immunogen

Purified recombinant fragment of human VIM (AA: 2-466) expressed in E. Coli.

Application &
Dilution Ratio

Application	Dilution Ratio
WB WB: Western Blot	1:500-1:2000
IHC-P IHC-P: Immunohistochemistry-Paraffin	1:200-1:1000
FC FC: Flow Cytometry	1:200-1:400
ELISA ELISA: Enzyme Linked Immunosorbent Assay	1:10000

Reinheit	affinity purified.	Conjugation	Non-conjugated
Modification	Unmodified	Isotype	IgG2a

Appearance

Liquid

Formulation

Supplied in PBS with 0.05% sodium azide

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Versand

Shipping with blue ice.

Background

Function：Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells. Vimentin is attached to the nucleus, endoplasmic reticulum, and mitochondria, either laterally or terminally. Plays a role in cell directional movement, orientation, cell sheet organization and Golgi complex polarization at the cell migration front (By similarity). Protects SCRIB from proteasomal degradation and facilitates its localization to intermediate filaments in a cell contact-mediated manner (By similarity); Involved with LARP6 in the stabilization of type I collagen mRNAs for CO1A1 and CO1A2

Subcellular Localization：Cytoplasm; Cytoplasm, cytoskeleton; Nucleus matrix; Cell membrane

Expression：
Tissue_specificity:It is highly expressed in fibroblasts, expressed in small amounts in T cells and B cells, and expressed very low or not at all in Burkitt lymphoma cell lines. It is expressed in many hormone-independent breast cancer cell lines.

Induction:Up-regulated by muramyl-dipeptide and lipopolysaccharide

Subunit：Homomer assembled from elementary dimers (PubMed:20176112). Identified in complexes that contain VIM, EZR, AHNAK, BFSP1, BFSP2, ANK2, PLEC, PRX and spectrin (By similarity). Interacts with BCAS3 (PubMed:17505058). Interacts with LGSN (By similarity). Interacts with SYNM (By similarity). Interacts (via rod region) with PLEC (via CH 1 domain) (By similarity). Interacts with PLEC isoform 1C (PubMed:24940650). Interacts with STK33 (PubMed:18811945). Interacts with LARP6 (PubMed:21746880). Interacts with RAB8B (By similarity). Interacts with TOR1A; the interaction associates TOR1A with the cytoskeleton (PubMed:16361107, PubMed:18827015). Interacts with TOR1AIP1 (PubMed:16361107). Interacts with DIAPH1 (PubMed:23325789). Interacts with EPPK1; interaction is dependent of higher-order structure of intermediate filament (PubMed:16923132). Interacts with the non-receptor tyrosine kinase SRMS; the interaction leads to phosphorylation of VIM (PubMed:29496907). Interacts with NOD2 (PubMed:27812135). Interacts (via head region) with CORO1C (By similarity). Interacts with HDGF (isoform 2) (PubMed:26845719). Interacts with PRKCE (via phorbol-ester/DAG-type 2 domain) (PubMed:18408015). Interacts with BFSP2 (By similarity). Interacts with PPL (By similarity). Interacts (via rod domain) with PKP1 (PubMed:10852826). Interacts with PKP2 (PubMed:10852826). Interacts with SCRIB (via PDZ domains); the interaction protects SCRIB from proteasomal degradation and facilitates SCRIB localization to intermediate filaments, the interaction is reduced by cell contact inhibition (PubMed:19386766)

Synonyms

FLJ36605; VIM

Dokumentation

User Guide for Antibodies (1077 KB)